Liver Cancer News & Features

Mutations in IDH1/2 Seen in Intrahepatic Bile Duct Cancers

January 26, 2012

Mutations found in about a quarter of cholangiocarcinomas of intrahepatic origin.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Everolimus combination improved progression-free survival in neuroendocrine tumors

Delicia Honen Yard December 14, 2011

Progression-free survival improved in patients with advanced neuroendocrine tumors when everolimus rather than placebo was used in combination with octreotide long-acting repeatable.
 

Diabetes drug helps prevent growth of breast cancer cells

Delicia Honen Yard December 09, 2011

Metformin, a widely used agent in the treatment of type 2 diabetes, stopped a number of natural and man-made chemicals from stimulating the growth of breast cancer cells.
 

Cancer risk doubles for organ-transplant recipients

Delicia Honen Yard November 21, 2011

Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have twice as great a risk for diverse infection-related and unrelated cancers.
 

Caffeine: The new sunblock?

Delicia Honen Yard September 02, 2011

Applying caffeine directly to the skin may eventually prove to help prevent sunlight-induced skin cancer, suggest the findings from a recent mouse study.
 

Radioembolization attains survival in liver cancer

Delicia Honen Yard August 29, 2011

A multicenter study conducted across Europe indicates that the liver-directed therapy, radioembolization, can be used to achieve survival in persons with hepatocellular carcinoma—including those with advanced disease and few treatment options.
 

Current alcohol consumption guidelines will not prevent cancer

Delicia Honen Yard July 27, 2011

An analysis published online by CMAJ charges that current guidelines for alcohol consumption are inadequate for cancer prevention and that new international guidelines are needed.
 

Experts discuss their predictions for radiation medicine

Bryant Furlow July 08, 2011

Presentations on emerging standards of care in radiotherapy from the Future of Radiation Medicine 2011 symposium are reviewed.
 

Celecoxib may be new weapon in fight against liver cancer

Delicia Honen Yard June 06, 2011

A cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug (NSAID) usually prescribed to relieve arthritis pain appears to be an effective treatment for liver cancer.
 

Liver Cancer Clinical Trials

Clinical Trial: Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Clinical Trial: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Clinical Trial: Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot be Removed by Surgery or Transplant

Clinical Trial: Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis

Clinical Trial: Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets

 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions